Details of the Drug

General Information of Drug (ID: DMIW5P1)

• Drug Name: BPM 31510

Indication

Disease Entry	ICD 11	Status	REF
Glioma	2A00.0	Phase 2	[1]
Pancreatic cancer	2C10	Phase 2	[2]
Epidermolysis bullosa	EC3Z	Phase 1	[3]

• Drug Type: Lipid-drug conjugate
• Cross-matching ID: TTD ID: D4MZR2
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT04752813) A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT02650804) A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients. U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02793960) Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health.